Connor, Clark & Lunn Investment Management (CC&L)’s Tempest Therapeutics TPST Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-34	Closed	-$187K	–	947
2017 Q1	$187K	Buy	34 +15	+79%	+$69.9K	﹤0.01%	808
2016 Q4	$83K	Buy	+19	New	+$237K	﹤0.01%	844
2015 Q3	–	Sell	-8	Closed	-$657K	–	787
2015 Q2	$657K	Sell	8 -12	-60%	-$1.1M	0.01%	389
2015 Q1	$2.02M	Buy	20 +15	+300%	+$2M	0.02%	231
2014 Q4	$668K	Buy	+5	New	+$366K	0.01%	353

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TPST Position: Q2 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 34 shares — an estimated $187K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TPST in Q4 2014 and held it in 5 quarters. The position peaked at $2.02M in Q1 2015. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 34 Tempest Therapeutics shares in Q2 2017, an estimated $187K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Tempest Therapeutics in Q4 2014 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Tempest Therapeutics position peaked at $2.02M in Q1 2015.
54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2017, filed 14 Aug 2017.